Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.92 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.92 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.52 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13125941 | 0.98 | ALDH1A1 (0.89) | ALDH1A1MAPK1APOBEC3AAPOBEC3GSMN1; SMN2 | |
| SCHEMBL170013 | 0.96 | ALDH1A1 (1.00) | ALDH1A1MAPK1APOBEC3AAPOBEC3GSMN1; SMN2 | |
| Bromide SCHEMBL3450128 | 0.94 | ALDH1A1 (0.96) | ALDH1A1MAPK1APOBEC3AAPOBEC3GSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL30189955 | 0.94 | ALDH1A1 (0.96) | ALDH1A1MAPK1APOBEC3AAPOBEC3GSMN1; SMN2 | |
| SCHEMBL13125914 | 0.88 | ALDH1A1 (0.78) | ALDH1A1MAPK1APOBEC3AAPOBEC3GSMN1; SMN2 | |
| SCHEMBL6118325 | 0.76 | ALDH1A1 (0.56) | ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA | |
| SCHEMBL12938269 | 0.74 | ALDH1A1 (0.59) | ALDH1A1MAPK1APOBEC3AAPOBEC3GSMN1; SMN2 | |
| SCHEMBL13125933 | 0.74 | ALDH1A1 (0.54) | ALDH1A1MAPK1APOBEC3AAPOBEC3GSMN1; SMN2 | |
| SCHEMBL6862670 | 0.73 | ALDH1A1 (0.63) | ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA | |
| SCHEMBL2035154 | 0.72 | ALDH1A1 (0.61) | ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421871-B1 | THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2015-09-16 | — | — | EP | disclosed |
| US-8779154-B2 | Fused ring compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2014-07-15 | — | — | US | disclosed |
| US-8779154-B2 | Fused ring compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2014-07-15 | — | — | US | disclosed |
| US-8389736-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389736-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389736-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-05 | — | — | US | disclosed |
| US-8288379-B2 | Thia-triaza-cyclopentazulenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-8288379-B2 | Thia-triaza-cyclopentazulenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-8288379-B2 | Thia-triaza-cyclopentazulenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| EP-2421871-A1 | THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2012-02-29 | — | — | EP | disclosed |
| US-20110112087-A1 | Thia-triaza-cyclopentazulenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-12 | — | — | US | disclosed |
| US-20110112087-A1 | Thia-triaza-cyclopentazulenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-12 | — | — | US | disclosed |
| WO-2010122071-A1 | THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010122071-A1 | THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273839-A1 | Compounds Having Activity in Correcting Mutant-CFTR Processing and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-10-28 | — | — | US | disclosed |
| US-20100273839-A1 | Compounds Having Activity in Correcting Mutant-CFTR Processing and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-10-28 | — | — | US | disclosed |
| US-20100273839-A1 | Compounds Having Activity in Correcting Mutant-CFTR Processing and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-10-28 | — | — | US | disclosed |
| US-20080132513-A1 | FUSED RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132513-A1 | FUSED RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2008-06-05 | — | — | US | disclosed |
| WO-2008039520-A2 | FUSED RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112087-A1 | Thia-triaza-cyclopentazulenes | CCNA1, MKI67, CCNT1 | ALDH1A1 147/4885MAPK1 1092/4885APOBEC3A 4607/4885 |
| US-20080132513-A1 | FUSED RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | NOD2, RORC, NLRP3 | ALDH1A1 2365/4885MAPK1 3193/4885APOBEC3A 3639/4885 |
| US-20100273839-A1 | Compounds Having Activity in Correcting Mutant-CFTR Processing and Uses Thereof | CFTR, ABCC5, ABCB11 | ALDH1A1 3083/4885MAPK1 4432/4885APOBEC3A 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.